DK164700B - 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider - Google Patents

3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider Download PDF

Info

Publication number
DK164700B
DK164700B DK269090A DK269090A DK164700B DK 164700 B DK164700 B DK 164700B DK 269090 A DK269090 A DK 269090A DK 269090 A DK269090 A DK 269090A DK 164700 B DK164700 B DK 164700B
Authority
DK
Denmark
Prior art keywords
alkyl
amino
phenyl
alkoxy
hydroxy
Prior art date
Application number
DK269090A
Other languages
English (en)
Other versions
DK164700C (da
DK269090A (da
DK269090D0 (da
Inventor
Aldo Antonio Algieri
Ronnie Ray Crenshaw
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of DK269090A publication Critical patent/DK269090A/da
Publication of DK269090D0 publication Critical patent/DK269090D0/da
Publication of DK164700B publication Critical patent/DK164700B/da
Application granted granted Critical
Publication of DK164700C publication Critical patent/DK164700C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)

Description

i
DK 164700 B
Den foreliggende opfindelse angår hidtil ukendte 3,4-disubstitue-rede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider, der er nyttige som mellemprodukter ved fremstillingen af de i dansk patentansøgning nr.
3718/80 (svarende til fremlæggelsesskrift nr. 160.611 B) omhandlede 5 histamin ^-antagonister.
Disse histamin Hg-antagonister, som er nyttige til behandling af sygdommen peptisk ulcer, har formlen (O) p 10 ^s\
N N
M1 ‘ A-(CH2)raZ(CH2)nNH R1 hvori 15 p betegner 1 eller 2, 1 2 3 R betegner hydroxy eller NR R , 2 3 R og R hver især uafhængigt af hinanden betegner hydrogen, (lavere)al kyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(1avere)-alkyl, cyclo(lavere)alkyl(lavere)alkyl, hydroxy(lavere)al kyl, (lavere)-20 alkoxy(lavere)al kyl, (lavere)alkylthio(lavere)alkyl, amino(lavere)al kyl, (lavere)al kyl amino(lavere)al kyl, di(lavere)al kyl amino(lavere)al kyl, pyrroli di no(1avere)alky1, p i peri d i no(1avere)al kyl, morpholi no(1avere)-alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)-alkylamino, di(lavere)al kyl amino, 2,2,2-trifluorethyl, 2-fluorethyl, 25 hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)-alkyl, amidino, (lavere)alkylamidino, A'-iCfy^Z'(CH2)n/-, phenyl, phenyl(lavere)al kyl, substitueret phenyl eller substitueret phenyl -(lavere)al kyl, hvori phenylringen kan indeholde en eller to substi-tuenter uafhængigt valgt blandt (1avere)al kyl, hydroxy, (lavere)-30 alkoxy og halogen eller en substituent valgt blandt methyl endioxy, 2
trifluormethyl og di(lavere)alkylamino, under den forudsætning at R
3 og R ikke begge er cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, (lavere)alkyl amino, di(lavere)alkylamino, hydroxy, (lavere)-alkoxy, cyano, amidino, (lavere) al kyl amid i no eller A'-iCHg)^ 35 Z'(CH2)n,-, eller R2 og R3 betegner tilsammen -CHgCHgXiCHg)^, r er et helt tal fra 1 til 3, inklusive, 4 X betegner methylen, svovl, oxygen eller N-R under den forudsætning, at når r er 1, er X methylen,
DK 164700B
2 4 R betegner hydrogen, (lavere)al kyl, (lavere)alkenyl, (lavere)-alkynyl, (lavere)alkanoyl eller benzoyl, m og m' er hver især uafhængigt af hinanden et helt tal fra O til 2, inklusive, 5 n og n' er hver især uafhængigt af hinanden et helt tal fra 2 til 4, inklusive, Z og V er hver især uafhængigt af hinanden svovl, oxygen eller methyl en, A og A' er hver især uafhængigt af hinanden phenyl, imidazolyl, 10 thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazo-lyl, oxadiazolyl, furyl, thienyl eller pyridyl, under den forudsætning at A og A' uafhængigt af hinanden kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)-15 alkoxy, -(CH2)qN=C og -(CH2)qNR5R6 20 og den anden er udvalgt blandt (lavere)al kyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl og (lavere)alkoxy, q er et helt tal fra 0 til 6, inklusive, begge R er uafhængigt af hinanden som ovenfor defineret, eller de to R4-grupper kan tilsammen 25 betegne ethylen, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere) - alkyl, (lavere) al kenyl, (lavere) al kynyl, cycl o (lavere) al kyl eller phenyl, under den forudsætning at R og R ikke begge kan være 5 6 cyclo(lavere)al kyl eller phenyl, eller R og R kan sammen med det 30 nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperidino, methyl piperidino, N-methylpiperazino eller homopiperidino, eller et ikke-toxisk, farmaceutisk acceptabelt salt, hydrat, solvat eller N-oxid deraf.
De 3,4-disubstituerede 1,2,5-thiadiazol-l-oxider og -1,1-dioxider 35 ifølge opfindelsen har den almene formel (XVII) 3
DK 164700 B
(0)P
N N XVII
M
5 HS(CH2)nH/ NR2R3 hvori p er 1 eller 2, n er et helt tal fra 2 til 4, inklusive, 2 3 10 R og R hver især uafhængigt af hinanden betegner hydrogen, (lavere)- alkyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(lavere)al kyl, cyclo- (lavere)alkyl(lavere)alkyl, hydroxy(lavere)al kyl, (lavere)alkoxy- (1avere)alky1, (1 avere)al kylth i o(1avere)al kyl, ami no(1avere)al kyl, (1avere)al kyl ami no(1avere)al kyl, di(1avere)al kyl ami no(1avere)al kyl, 15 pyrrolidino(lavere)alkyl, piperidino(lavere)alkyl, morpholino(lavere)- alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)- alkyl amino, di(lavere)al kyl ami no, 2,2,2-tri fluorethyl, 2-fluorethyl, hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)al kyl, amidino, (lavere)alkylamidino, A'-tCHgJ^Z'(CH2)n/-, phenyl, phenyl- 20 (lavere)al kyl, substitueret phenyl eller substitueret phenyl(lavere)- alkyl, hvori phenylringen kan indeholde én eller to substituenter uafhængigt udvalgt blandt (lavere)alkyl, hydroxy, (lavere)alkoxy og halogen, eller én substituent udvalgt blandt methyl endioxy, trifluor- 2 3 methyl og di(lavere)alkylamino, under den forudsætning at R og R ikke 25 begge kan være cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, (lavere)alkyl amino, di(lavere)al kyl amino, hydroxy, (lavere)alkoxy, cyano, amidino, (lavere)alkylamidino eller A'-(CH2)m,Z'(CH2)n/-> eller R^ og R3 kan tilsammen betegne -CHgCHgXiCHjJp-, r er et helt tal fra 1 til 3, inklusive, 4 30 X betegner methylen, svovl, oxygen eller N-R , under den forudsætning, at når r er 1, betegner X methylen, R* betegner hydrogen, (1avere)al kyl, (1avere)alkenyl, (1avere)alkynyl, (lavere)alkanoyl eller benzoyl, m' er et helt tal fra 0 til 2, inklusive, 35 n' er et helt tal fra 2 til 4, inklusive, 1' betegner svovl, oxygen eller methylen, A' betegner phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-xazolyl, triazolyl, thi adi azolyl, oxadiazolyl, furyl, thienyl eller
DK 164700 B
4 pyridyl, under den forudsætning at A' kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, · hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)alkoxy, 5 NHR4 -(CH2>qN=CC^ °9 -(CH2)qNR5R6 NHR4 og den anden er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, 10 halogen, amino, hydroxymethyl og (lavere)alkoxy, q er et helt tal fra O til 6, inklusive, 4 hvert R er uafhængigt af hinanden som ovenfor defineret, eller de to 4 R -grupper kan tilsammen betegne ethyl en, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere)- 15 al kyl, (lavere) alkenyl, (lavere)alkynyl, cyclo(lavere)alkyl eller 5 6 phenyl, under den forudsætning at R og R ikke begge kan være cyclo- 5 6 (lavere)al kyl eller phenyl, eller R og R kan sammen med det nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperi-dino, methyl piperidino, N-methylpiperazino eller homopiperidino, 20 eller et salt, hydrat, solvat eller N-oxid deraf.
Forbindelserne med formlen I kan fremstilles ud fra en forbindelse med formlen XVII via den i reaktionsskemaet nedenfor anførte reaktionsvej.
Omsætningerne udføres i et inert organisk opløsningsmiddel. Det har 25 vist sig, at methanol er et hensigtsmæssigt og let tilgængeligt opløsningsmiddel. Reaktionstemperaturen er ikke kritisk. De fleste udgangsmaterialer er temmelig reaktive, og det foretrækkes at udføre omsætningen ved en temperatur under stuetemperatur, f.eks. 0-10°. Med nogle mindre reaktive forbindelser er det hensigtsmæssigt at udføre 30 omsætningen ved stuetemperatur. Undertiden er det ønskeligt senere at hæve reaktionsblandingens temperatur (f.eks. til 50-60°) for at fuldende omsætningen.
5
DK 164700 B
(O) p /sv
Reaktionsskema „ x ---- N n M, R7 R7
II
/R10H \^S(CH2)nHH2 (0)p (0)p
NN N N
W // \\J
R7 R10 HS(CH2)n!IH R7 χ„ XI11 \ / \hS(CH_) NH- / \ 2 n 2 /r10h (0) /s\
N N
\\ // ^
1 / ^ R10 HS(CH2)nNH K
A(CH2)mX
V
(0)p /S\ K.
A(CH-) S(CH-) NH R
λ m i n I c 6
DK 164700 B
I reaktionsskemaet betegner en let fraspaltelig gruppe udvalgt blandt halogen, (lavere)alkoxy, (lavere)alkylthio, phenoxy eller phenylthio, som kan indeholde 1 eller 2 substituenter udvalgt blandt 10 2 3 halogen, (lavere)al kyl, (lavere)alkoxy og nitro, R -NR R , og X er en 5 konventionel fraspaltelig gruppe. Egnede fraspaltelige grupper omfatter f.eks. fluor, chlor, brom, iod, -O^SR^, hvori R** betegner (lavere)-alkyl (f.eks. methansulfonat), aryl eller substitueret aryl (f.eks. benzensul fonat, p-brombenzensulfonat eller p-toluensul fonat), O^SF, acetoxy og 2,4-dinitrophenoxy. Af nemheds og økonomiske grunde fore-10 trækkes det at anvende en forbindelse, hvori X betegner chlor. Omsætningen af forbindelsen med formlen XVII med AiCHg)^ kan udføres i et hvilket som helst inert organisk opløsningsmiddel, såsom en alkanol, acetonitril, dimethyl formamid, dimethyl sulfoxid, acetone, og lignende.
Det foretrækkes at udføre omsætningen i en alkanol, såsom methanol, 15 ethanol eller isopropanol. Reaktionstemperaturen er ikke kritisk; omsætningen kan udføres ved temperaturer på fra ca. 0° til ca. 200°C. Ved lave temperaturer er omsætningen langsom, medens høje temperaturer normalt fører til mindre rene produkter på grund af nedbrydning og dannelse af biprodukter. Det foretrækkes sædvanligvis at udføre omsæt-20 ningen ved stuetemperatur. Omsætningen af forbindelsen med formlen XVII med AiCHgJrøX til dannelse af forbindelsen med formlen Ic udføres fortrinsvis i nærværelse af en base, som letter omsætningen ved at optræde som en syreacceptor. Egnede baser omfatter f.eks. NaOH, KOH, LiOH, triethylamin, dimethylanilin, natriumethoxid, og lignende. Hvor X 25 betegner hydroxyl, kan omsætningen udføres i koncentreret mineral syre, f.eks. HC1. Alle mellemprodukter med formlen XIII, XIV og XVII er hidtil ukendte forbindelser.
Eksempel 1 30 3-methyl ami no-4-(2-mercaptoethylami no)-1,2,5-th i adi azol-1,1-di oxi d Eh opløsning af 2-aminoethanthiol (fra hydrochloridet 1,91 g, 16,8 mmol) i 20 ml methanol sattes dråbevis i løbet af en periode på 15 minutter til en godt omrørt suspension af 3,4-dimethoxy-l,2,5--thiadiazol-l,l-dioxid (3,0 g, 16,8 mmol) i 250 ml methanol, der var 35 blevet afkølet til 1° i et is-vandbad. Efter 10 minutter ved 2-4° bob-ledes methylamin til den afkølede opløsning i 6 minutter, og omrøring fortsattes i yderligere 30 minutter ved omgivelsernes temperatur. Reaktionsblandingen inddampedes under formindsket tryk, og remanensen 7
DK 164700 B
anbragtes på 45 g silicagel og kromatograferedes under anvendelse af en gradienteluering af methylenchlorid-methanol. De relevante fraktioner forenedes og inddampedes, og produktet (2,43 g) krystalliseredes fra absolut ethanol. Omkrystallisation fra absolut ethanol gav titelfor-5 bindeisen, snip. 259-260° (dek.).
Analyse for C5Hjo^402S2:
Beregnet: C: 27,03, H: 4,54, N: 25,20,
Fundet: C: 27,13, H: 4,55, N: 24,86.
10 Eksempel 2 3-methylamino-4-(2-mercaptoethylamino)-1,2,5-thi adi azol-1-oxid
En opløsning af 2-aminoethanthiol (fra hydrochloridet, 2,04 g, 18,0 mmol) i 25 ml methanol sattes dråbevis i løbet af en periode på 30 minutter til en godt omrørt suspension af 3,4-dimethoxy-l,2,5-15 -thiadiazol-l-dioxid (2,92 g, 18,0 mmol) (fremstillet ifølge eksempel 4, trin A) i 150 ml methanol, der var blevet afkølet til 3° i et is--vandbad. Efter 10 minutter bobledes vandfri methylamin til opløsningen i 6 minutter, og omrøring fortsattes ved omgivelsernes temperatur i yderligere 20 minutter. Reaktionsblandingen inddampedes 20 under reduceret tryk, og remanensen anbragtes på 45 g silicagel og kromatograferedes under anvendelse af en gradienteluering af methy-lenchlorid-methanol. De relevante fraktioner forenedes og inddampedes til dannelse af 2,74 g af produktet. Omkrystallisation fra methanol og derpå 95% ethanol gav titel forbindel sen, smp. 191-193°.
25
Eksempler på fremstillingen af slutforbindelser med formlen (I) ud fra forbindelser ifølge opfindelsen.
Eksempel 3 30 3-(2-((5-dimethylaminomethyl-2-furyl)methylthio1ethylamino)-4-methylamino-l,2,5-thiadiazol-l,l-dioxid
En blanding indeholdende 3-methylamino-4-(2-mercaptoethylamino)- l,2,5-thiadiazol-l,l-dioxid (1,0 g, 4,5 mmol) (fremstillet i eksempel 1) og 5-dimethylaminomethyl-2-furanmethanol (0,82 g, 4,5 mmol) (fremstillet 35 i henhold til den i J. Chem. Soc., 4728 (1958) beskrevne fremgangsmåde) i 20 ml koncentreret saltsyre omrørtes i et is-vandbad i 2 timer og henstod derefter ved 0° i 64 timer. Reaktionsblandingen omrørtes ved omgivelsernes temperatur under reduceret tryk, og remanensen deltes 8
DK 164700 B
mellem vand og methylenchlorid. Den vandige fase gjordes basisk med natriumbicarbonat og ekstraheredes med methylenchlorid. Den forenede organiske fase vaskedes med mættet saltvandsopløsning, tørredes og inddampedes under reduceret tryk. Remanensen anbragtes på 25 g silicagel 5 og kromatograferedes under anvendelse af en gradieneluering af methylenchlorid-methanol. Den relevante fraktion inddampedes, og produktet krystalliseredes fra methanol. Omkrystallisation fra methanol gav titel forbindel sen, smp. 92-96°.
10 Eksempel 4 3-(2-Γ(5-dimethylaminomethyl-2-furyl)methyl hi olethyl amino)-4-methyl -amino-1,2,5-thiadiazol-l-oxid Når 3-methyl amino-4-(2-mercaptoethylamino)-1,2,5-thiadiazol-l-oxid (fremstillet i eksempel 2) behandles med ca. 1 ækvivalent 5-dimethyl ami-15 nomethyl-2-furanmethanol i koncentreret saltsyre i henhold til den i eksempel 3, beskrevne fremgangsmåde fås titel forbindel sen; identisk med produktet ifølge eksempel 13. Smp. 86-92°C.
Analyse for
Beregnet: C: 45,46, H: 6,16, H: 20,39, S: 18,67.
20 Fundet: C: 45,24, H: 6,24, N: 20,41, S, 18,90.

Claims (1)

  1. 9 DK 164700 B 1. 3,4-disubstitueret 1,2,5-thiadiazol-1-oxid eller -1,1-oxid med formlen 5 p /> H us(Oi2)nm nrV hvori p er 1 eller 2, n er et helt tal fra 2 til 4, inklusive, 2 3 R og R hver især uafhængigt af hinanden betegner hydrogen, (1avere)- 15 al kyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(lavere)al kyl, cyclo- (lavere)alkyl(lavere)alkyl, hydroxy(lavere)alkyl, (lavere)alkoxy- (lavere)al kyl, (lavere)al kyl thio(lavere)al kyl, amino(lavere)al kyl, (lavere)al kyl amino(lavere)al kyl, di(lavere)alkylamino(lavere)alkyl, pyrrol i d i no(1avere)al kyl, p i peri di no(1avere)alky1, morpholi no(1avere)- 20 alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)- alkylamino, di(lavere)al kyl amino, 2,2,2-trifluorethyl, 2-fluorethyl, hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)al kyl, amidino, (lavere)al kyl amidi no, A/'(CH2)ni/Z,(CH2)n/-, phenyl, phenyl- (lavere)al kyl, substitueret phenyl eller substitueret phenyl(lavere)- 25 al kyl, hvori phenylringen kan indeholde én eller to substituenter uafhængigt udvalgt blandt (lavere)al kyl, hydroxy, (lavere)alkoxy og halogen, eller én substituent udvalgt blandt methyl endioxy, trifluor- 2 3 methyl og di(1averejalkyl amino, under den forudsætning at R og R ikke begge kan være cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, 30 (lavere)al kyl amino, di(lavere)al kyl ami no, hydroxy, (lavere)alkoxy, cyano, amidino, (lavere)alkylamidino eller A,-(CH2)m,Z/(CH2)n,-, eller R^ og R^ kan tilsammen betegne -CH2CH2X(CH2)r-, r er et helt tal fra 1 til 3, inklusive, X betegner methylen, svovl, oxygen eller N-R4, under den forudsætning, 35 at når r er 1, betegner X methylen, R4 betegner hydrogen, (1avere)al kyl, (1avere)alkenyl, (1avere)alkynyl, (lavere)alkanoyl eller benzoyl, m' er et helt tal fra 0 til 2, inklusive, 10 DK 164700 B n' er et helt tal fra 2 til 4, inklusive, V betegner svovl, oxygen eller methyl en, A' betegner phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-xazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl eller 5 pyridyl, under den forudsætning at A' kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)alkoxy, ^—-NHR4 10 -(CH2^qN=CC^ °9 -(CH2)qNR5R6 NHR^ og den anden er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl og (lavere)alkoxy, 15. er et helt tal fra O til 6, inklusive, hvert R er uafhængigt af hinanden som ovenfor defineret, eller de to 4 R -grupper kan tilsammen betegne ethyl en, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere)- alkyl, (lavere) alkenyl, (lavere) al kynyl, cycl o (lavere) al kyl eller 20 phenyl, under den forudsætning at R og R ikke begge kan være cyclo- 5 6 (lavere)alkyl eller phenyl, eller R og R kan sammen med det nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperi-dino, methyl piperidino, N-methylpiperazino eller homopiperidino, eller et salt, hydrat, sol vat eller N-oxid deraf. 25 30 35
DK269090A 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider DK164700C (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7251779A 1979-09-04 1979-09-04
US7251779 1979-09-04
US11718280A 1980-01-31 1980-01-31
US11718280 1980-01-31
US16383180A 1980-06-07 1980-06-07
US16383180 1980-06-07

Publications (4)

Publication Number Publication Date
DK269090A DK269090A (da) 1990-11-09
DK269090D0 DK269090D0 (da) 1990-11-09
DK164700B true DK164700B (da) 1992-08-03
DK164700C DK164700C (da) 1992-12-21

Family

ID=27372107

Family Applications (4)

Application Number Title Priority Date Filing Date
DK371880A DK160611C (da) 1979-09-04 1980-09-01 Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
DK268990A DK164363C (da) 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider
DK269190A DK164702C (da) 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider
DK269090A DK164700C (da) 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK371880A DK160611C (da) 1979-09-04 1980-09-01 Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
DK268990A DK164363C (da) 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider
DK269190A DK164702C (da) 1979-09-04 1990-11-09 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider

Country Status (23)

Country Link
US (1) US4374248A (da)
AR (1) AR240559A1 (da)
AT (2) AT376978B (da)
CA (4) CA1167841A (da)
CH (2) CH649764A5 (da)
CS (1) CS235951B2 (da)
CY (2) CY1360A (da)
DE (2) DE3033169C2 (da)
DK (4) DK160611C (da)
FI (1) FI76795C (da)
GB (2) GB2067987B (da)
HK (2) HK41387A (da)
IE (2) IE50997B1 (da)
KE (2) KE3685A (da)
LU (1) LU82753A1 (da)
MY (2) MY8700735A (da)
NL (3) NL189197C (da)
NO (4) NO160003C (da)
NZ (1) NZ194831A (da)
PT (1) PT71764B (da)
SE (5) SE449099B (da)
SG (1) SG61187G (da)
ZW (1) ZW20580A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040696B1 (en) * 1980-04-30 1986-08-27 Merck & Co. Inc. Aminothiadiazoles as gastric secretion inhibitors
US4760075A (en) * 1980-10-02 1988-07-26 Eli Lilly And Company N-thiazolylmethylthioalkyl-N-alkyl-amidines and related compounds
US4904792A (en) * 1980-10-02 1990-02-27 Eli Lilly And Company N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds
US4471122A (en) * 1981-03-03 1984-09-11 Bristol-Myers Company Thiadiazole histamine H2 -antagonists
US4362726A (en) 1981-04-24 1982-12-07 Merck & Co., Inc. Substituted-1,2,5-thiadiazole-1-oxide compounds, compositions and use
EP0065823A1 (en) * 1981-05-13 1982-12-01 Imperial Chemical Industries Plc Heterocyclic guanidines as histamine H-2 antagonists
IE53068B1 (en) * 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
ATE19880T1 (de) * 1981-08-24 1986-06-15 Merck & Co Inc Thiadiazole oxyde mit antisekretorischer wirkung.
GR77847B (da) * 1981-12-14 1984-09-25 American Home Prod
ES8404683A1 (es) * 1982-03-29 1984-05-16 Bristol Myers Co Un procedimiento para la preparacion de antagonistas de los receptores hidrogeno de la histamina.
US4517366A (en) * 1982-03-29 1985-05-14 Bristol-Myers Company Intermediates for preparing 3,4-diamino-1,2,5-thiadiazoles
US4578471A (en) * 1982-03-29 1986-03-25 Bristol-Myers Company Substituted amino alkyl pyridyl ethanediimidamides
US4528375A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4528377A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4528378A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
FI832519L (fi) * 1982-07-12 1984-01-13 Bristol Myers Co Farmaceutiska foerfaranden och sammansaettningar
US4520025A (en) * 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
EP0105732A3 (en) * 1982-10-01 1985-09-04 Beecham Group Plc Histamine h2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series
US4461900A (en) * 1983-03-14 1984-07-24 American Home Products Corporation 4,5-Dihydrothiadiazole 1,1-dioxide derivatives
US4440933A (en) * 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles
AT387384B (de) * 1983-03-16 1989-01-10 Bristol Myers Co Verfahren zur herstellung von thiadiazolderivaten
GB2138803B (en) * 1983-04-26 1986-06-18 Shionogi & Co 2-guanidino-4-hydroxymethylthiazole and derivatives thereof
US4543352A (en) * 1983-04-29 1985-09-24 William H. Rorer, Inc. Naphthalene aminoalkylene ethers and thioethers, and their pharmaceutical uses
DE3326545A1 (de) * 1983-07-22 1985-01-31 Ludwig Heumann & Co GmbH, 8500 Nürnberg Propan-2-ol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4529731A (en) * 1983-09-22 1985-07-16 American Home Products Corporation Thiadiazolediamine derivative with histamine H-2 receptor inhibiting properties
US4692531A (en) * 1984-06-22 1987-09-08 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4644006A (en) * 1984-06-22 1987-02-17 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4612309A (en) * 1984-10-23 1986-09-16 William H. Rorer, Inc. Antisecretory bicyclic benzo-oxy heterocyclic ethers and thioethers
GB8501535D0 (en) * 1985-01-22 1985-02-20 Smith Kline French Lab Chemical compounds
US4728648A (en) * 1985-02-09 1988-03-01 Smith Kline & French Laboratories Limited Histamine antagonist triadiazole derivatives, compositions, and method of use therefor
GB8509276D0 (en) * 1985-04-11 1985-05-15 Smith Kline French Lab Pyridine derivatives
GB8510680D0 (en) * 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
CA1286297C (en) * 1985-06-13 1991-07-16 George S. Sach Pyridine derivatives
DE3532880A1 (de) * 1985-09-14 1987-03-26 Basf Ag 1,4-disubstituierte pyrazolderivate
GB8610867D0 (en) * 1986-05-02 1986-06-11 Smith Kline French Lab 3-hydroxypyridines
ES2008962A6 (es) * 1987-12-17 1989-08-16 Marga Investigacion Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
EP0960880A1 (en) * 1991-05-21 1999-12-01 Eli Lilly And Company Process for preparing intermediates to nizatidine and related compounds
US5248673A (en) * 1992-12-23 1993-09-28 Bristol-Myers Squibb Co. Bisamidine derivatives as thrombin inhibitors
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
US5767280A (en) * 1995-06-01 1998-06-16 Eli Lilly And Company Process for making heterocyclic compounds
EP1551818B1 (en) 2002-10-09 2009-02-04 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
US7338968B2 (en) 2003-12-19 2008-03-04 Schering Corporation Thiadiazoles AS CXC- and CC- chemokine receptor ligands
WO2005068460A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
WO2007002764A2 (en) 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
ATE486078T1 (de) 2005-06-29 2010-11-15 Schering Corp 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014009293A1 (en) 2012-07-13 2014-01-16 Basf Se New substituted thiadiazoles and their use as fungicides
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
CN105061360B (zh) * 2015-07-28 2018-06-19 首都师范大学 一种3,4-二氨基-1,2,5-噻二唑的提纯方法
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL22850A (en) * 1964-03-18 1968-12-26 Merck & Co Inc 3-chloro-1,2,5-thiazdiazole-4-carboxylic acid being an intermediate in the preparation of sulfa drugs
CH482712A (de) * 1964-10-01 1969-12-15 Merck & Co Inc Verfahren zur Herstellung von 3-Amino-1,2,5-thiadiazolen
US3564000A (en) * 1965-10-15 1971-02-16 Merck & Co Inc Process for preparing 3-chloro-4-hydroxy-1,2,5-thiadiazole derivatives
US3419573A (en) * 1965-10-15 1968-12-31 Merck & Co Inc 3-chloro-4-oxy-1,2,5-thiadiazoles, and a process for preparing same
DE1770152A1 (de) * 1968-04-08 1971-09-30 Lentia Gmbh Verfahren zur Herstellung von 3-Amino-4-brom-1,2,5-thiadiazol
US3657237A (en) * 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
US4104381A (en) * 1973-05-03 1978-08-01 Smith Kline & French Laboratories Limited Pharmacologically active compounds
AT348517B (de) * 1977-01-19 1979-02-26 Chemie Linz Ag Verfahren zur herstellung von reinem 3-methoxy- 4- (4'-aminobenzolsulfonamido) -1,2,5-thiadiazol
NZ186965A (en) * 1977-04-20 1980-02-21 Ici Ltd Guanidino derivatives and pharmaceutical compositions
US4165378A (en) * 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles
US4374836A (en) * 1978-10-16 1983-02-22 Imperial Chemical Industries Ltd. Antisecretory heterocyclic derivatives, process for their manufacture and pharmaceutical compositions containing them
EP0040696B1 (en) * 1980-04-30 1986-08-27 Merck & Co. Inc. Aminothiadiazoles as gastric secretion inhibitors
DE3168031D1 (en) * 1980-07-30 1985-02-14 Ici Plc Guanidine derivatives
ATE19880T1 (de) * 1981-08-24 1986-06-15 Merck & Co Inc Thiadiazole oxyde mit antisekretorischer wirkung.

Also Published As

Publication number Publication date
IE50997B1 (en) 1986-09-03
NO871420D0 (no) 1987-04-06
NL189197B (nl) 1992-09-01
CY1360A (en) 1987-08-07
NO160003C (no) 1989-03-01
CA1263114A (en) 1989-11-21
DK164702C (da) 1992-12-21
GB2067987A (en) 1981-08-05
CY1402A (en) 1987-12-18
DK269190D0 (da) 1990-11-09
ATA443480A (de) 1984-06-15
IE801851L (en) 1981-03-04
AR240559A1 (es) 1990-05-31
SE8006148L (sv) 1981-04-15
NL9201237A (nl) 1993-03-01
DK164363B (da) 1992-06-15
DK164363C (da) 1992-11-02
HK41387A (en) 1987-06-05
SE8403108L (sv) 1984-06-08
NO160003B (no) 1988-11-21
SE8403111L (sv) 1984-06-08
CH649764A5 (de) 1985-06-14
DE3033169A1 (de) 1981-03-19
SG61187G (en) 1987-10-23
CA1263115A (en) 1989-11-21
GB2067987B (en) 1984-07-11
NO161737B (no) 1989-06-12
NO802576L (no) 1981-03-05
NO862501L (no) 1987-03-05
DK371880A (da) 1981-03-05
GB2132190B (en) 1985-01-03
GB8318949D0 (en) 1983-08-17
DK269190A (da) 1990-11-09
LU82753A1 (fr) 1981-04-17
SE449099B (sv) 1987-04-06
CS235951B2 (en) 1985-05-15
AT377257B (de) 1985-02-25
SE8403107L (sv) 1984-06-08
KE3742A (en) 1987-09-04
CA1248962A (en) 1989-01-17
NO162664C (no) 1990-01-31
MY8700585A (en) 1987-12-31
NO160781C (no) 1989-05-31
DK164702B (da) 1992-08-03
CA1167841A (en) 1984-05-22
FI802740A7 (fi) 1981-03-05
SE8403108D0 (sv) 1984-06-08
DE3033169C2 (de) 1989-08-03
PT71764B (en) 1983-04-28
NO162664B (no) 1989-10-23
NO161737C (no) 1989-09-20
PT71764A (en) 1980-09-30
GB2132190A (en) 1984-07-04
NL189197C (nl) 1993-02-01
MY8700735A (en) 1987-12-31
FI76795B (fi) 1988-08-31
DK160611C (da) 1991-09-16
NO871421D0 (no) 1987-04-06
ZW20580A1 (en) 1981-01-21
SE456582B (sv) 1988-10-17
SE456580B (sv) 1988-10-17
SE8403111D0 (sv) 1984-06-08
IE861175L (en) 1981-03-04
US4374248A (en) 1983-02-15
SE8403109D0 (sv) 1984-06-08
NL9201236A (nl) 1993-03-01
NO160781B (no) 1989-02-20
SE456581B (sv) 1988-10-17
SE8403107D0 (sv) 1984-06-08
DK164700C (da) 1992-12-21
DK268990A (da) 1990-11-09
FI76795C (fi) 1988-12-12
KE3685A (en) 1987-01-30
SE461733B (sv) 1990-03-19
IE51235B1 (en) 1986-11-12
DK269090A (da) 1990-11-09
SE8403109L (sv) 1984-06-08
HK89187A (en) 1987-12-11
ATA64584A (de) 1984-07-15
CH658055A5 (de) 1986-10-15
NO862501D0 (no) 1986-06-23
AT376978B (de) 1985-01-25
NL8004967A (nl) 1981-03-06
DK268990D0 (da) 1990-11-09
DK160611B (da) 1991-04-02
DK269090D0 (da) 1990-11-09
NZ194831A (en) 1984-11-09
DE3051146C2 (de) 1991-05-02

Similar Documents

Publication Publication Date Title
DK164702B (da) 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider
AU2007234843B2 (en) Inhibitors of histone deacetylase
ES2203831T3 (es) Derivados de sulfonamida, procedimiento para su preparacion, y su uso como medicamentos.
US6420367B1 (en) Pyrimidine derivatives exhibiting antitumor activity
CA2367368C (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
WO2008047109A1 (en) Thiazole derivatives as kinase inhibitors
CZ166498A3 (cs) Způsob přípravy 2-chlorthiazolových sloučenin a jejich použití
CS198297B2 (en) Method of producing derivatives of urea
FR2480751A1 (fr) 4,1-benzoxazepines et leur utilisation comme produits pharmaceutiques pour le systeme nerveux central
AU2004249697B2 (en) Thiazoline derivatives as selective androgen receptor modulators (SARMS)
CA2289572A1 (en) Novel hexahydro-1,4-diazepine derivatives or salts thereof
SU900813A3 (ru) Способ получени производных тиенопиридина
US4678855A (en) Substituted benzenesulfonamides
NO833478L (no) Tiatriazinderivater
Arranz et al. Synthesis and pharmacological evaluationof 2, 3-dihydro-3-oxo-4H-thieno [3, 4-e][1, 2, 4] thiadiazine 1, 1-dioxidesas voltage-dependent calcium channel blockers
NO163055B (no) Fremgangsmaate til fremstilling av substituerte 3,4-diamino-1,2,5-tiadiazoler.
NO851219L (no) Sulfamoylguanidinderivater.
DD153838A5 (de) Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-thiadiazol-1-oxiden und-1,1-dioxiden
NO153848B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive n-(arylthioalkyl)-n`-(aminoalkyl)-ureaderivater.
EP0175570A2 (en) Process for the preparation of aromatic-1,4-oxazepinones and thiones
US4094870A (en) 2-Substituted thio-1,4-benzodiazepine derivatives
Molina et al. Synthesis of 1, 2, 4-triazole and 1, 3, 4-thiadiazole derivatives from methyl 2-methyldithiocarbazate and heterocumulenes
NO851220L (no) Tiatriazinderivater
DE2419923A1 (de) Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
CA2442139C (en) Process for preparing 6-aryl-4h-s-triazolo[3,4-c]-thieno[2,3-e]-1,4-diazepines

Legal Events

Date Code Title Description
A0 Application filed
PBP Patent lapsed